PG18 A COST-EFFECTIVENESS EVALUATION-RETREATMENT WITH PEGYLATED INTERFERON ALFA 2B PLUS RIBAVIRIN IN HEPATITIS C PATIENTSWHO HAVE PREVIOUSLY RECEIVED INTERFERON-BASED THERAPY AND FAILED TO ATTAIN A SUSTAINED VIROLOGICAL RESPONSE
Nov 1, 2008, 00:00
10.1016/S1098-3015(10)66722-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)66722-8/fulltext
Title :
PG18 A COST-EFFECTIVENESS EVALUATION-RETREATMENT WITH PEGYLATED INTERFERON ALFA 2B PLUS RIBAVIRIN IN HEPATITIS C PATIENTSWHO HAVE PREVIOUSLY RECEIVED INTERFERON-BASED THERAPY AND FAILED TO ATTAIN A SUSTAINED VIROLOGICAL RESPONSE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)66722-8&doi=10.1016/S1098-3015(10)66722-8
First page :
Section Title :
Open access? :
No
Section Order :
557